Anti-tumor necrosis factor therapies in immune-mediated rheumatic diseases. Other observations from the clinic.
To date, over 2 million patients worldwide have been treated with anti-tumor necrosis factor (TNF) therapies, dramatically improving the treatment outcomes of immune-mediated inflammatory diseases (IMID). Observations from clinicians have identified some curious disconnects between clinical and radiographic outcomes, and the paradoxical occurrence of anti-TNF therapy-induced IMID such as psoriasis or reactivation of uveitis and Crohn's disease. These observations point to the need for a better understanding of the mechanisms underlying the ability of anti-TNF therapies to reduce inflammation and how this is linked to the pathogenesis of IMID.
Russell
Anthony S
AS
Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. russell@ualberta.ca
Rosenbaum
James T
JT
D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D018836:Inflammation Mediators / Q000037:antagonists & inhibitors* / Q000378:metabolism; D010010:Osteoclasts / Q000187:drug effects / Q000276:immunology; D011565:Psoriasis / Q000139:chemically induced / Q000276:immunology; D011859:Radiography; D012216:Rheumatic Diseases / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000276:immunology; D018570:Risk Assessment; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000378:metabolism; D014605:Uveitis / Q000139:chemically induced / Q000276:immunology
D018501:Antirheumatic Agents; D018836:Inflammation Mediators; D014409:Tumor Necrosis Factor-alpha